Skip to main content

Market Overview

Clovis Oncology Plummets After Rociletinib Approval Rejected

Share:

Shares of Clovis Oncology Inc (NASDAQ: CLVS) fell more than 5 percent on Tuesday. The company announced the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) met to discuss approval of the New Drug Application for Rociletinib.

Shares of Clovis Oncology closed Monday's session at $15.06; They were halted in Tuesday's pre-market session before resuming trade at 2:20 p.m. ET.

President and CEO of Clovis Oncology, Patrick J. Mahaffy, stated, “We are disappointed with today's outcome, as we believe in the strength of the data we presented for rociletinib. We will work with the FDA to evaluate the best path forward as it continues to review our application.”

Shares closed down more than 5.4 percent at $14.24.

 

Related Articles (CLVS)

View Comments and Join the Discussion!

Posted-In: rociletinibNews Health Care FDA Movers General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com